Colimycine: Un vieil antibiotique qu'il faut apprendre à connaître;Colimycin: An old antibiotic which has to be learnt to know

Archives de Pediatrie

Volumn 17, Issue SUPPL. 4, 2010, Pages

  Cohen, R ^a,b  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Association clinique et therapeutique infantile du Val de Marne ACTIV   (France)

Author keywords

Bact ries multi r sistantes; Colimycine; Polymixines

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; COLISTIMETHATE; COTRIMOXAZOLE; IMIPENEM; MINOCYCLINE; NEOMYCIN; RIFAMPICIN; SUCCINYLSULFATHIAZOLE; ANTIINFECTIVE AGENT; COLISTIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BRAIN TOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; ENTEROBACTERIACEAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; ACINETOBACTER; BACTERIAL INFECTION; BLOOD; DRUG COMBINATION; DRUG EFFECT; PSEUDOMONAS;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; HUMANS; PSEUDOMONAS;

EID: 77956305054     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(10)70920-9     Document Type: Article

References (20)

1. Li J., Nation R., Turnidge J., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601.
2. Landman D., Georgescu C., Martin D.A., et al. Polymyxins revisited. Clin Microbiol Rev 2008, 21:449-465.
3. Tamma P.D., Lee C.K. Use of colistin in children. Pediatr Infect Dis J 2009, 28:534-535.
4. Zavascki A.P., Li J. Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. Lancet Infect Dis 2008, 8:403-405.
5. Falagas M.E., Vouloumanou E.K., Rafailidis P.I. Systemic colistin use in children without cystic fibrosis: a systematic review of the littérature. Int J Antimicrob Agents 2009, 33:503. e1-503. e13.
6. Falagas M.E, Sideri G., Vouloumanou E.K., et al. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009, 28:123-128.
7. Iosifidis E., Antachopoulos C., Ioannidou M., et al. Colistin administration to pediatric and neonatal patients. Eur J Pedatr 2010, 169:867-874.
8. Oie S., Fukui Y., Yamamoto M., et al. In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa. BMC Infect Dis 2009, 9:123.
9. Gunderson B.W., Ibrahim K.H., Hovde L.B., et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003, 47:905-909.
10. Li J., Rayner C.R., Nation R.L., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006, 50:2946-2950.
11. Tan C.H., Li J., Nation R.L. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007, 51:3413-3415.
12. Bergen P.J., Li J., Nation R.L., et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008, 61:636-642.
13. Bulitta J.B., Yang J.C., Yohonn L., et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010, 54:2051-2062.
14. Walkty A., DeCorby M., Nichol K., et al. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob Agents Chemother 2009, 53:4924-4926.
15. Bergen P.J., Li J., Rayner C.R., et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50:1953-1958.
16. Plachouras D., Karvanen M., Friberg L.E., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009, 53:3430-3436.
17. Antachopoulos C, Karvanen M, Iosifidis E, et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother 2010 Jun 28 [Epub ahead of print].
18. Owen R.J., Li J., Nation R.L., et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007, 59:473-477.
19. Poudyal A., Howden B.P., Bell J.M., et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008, 62:1311-1318.
20. Dudhani R.V., Turnidge J.D., Coulthard K., et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010, 54:1117-1124.